Literature DB >> 22478817

The value of observational cohort studies for cancer drugs.

David R Spigel.   

Abstract

Randomized controlled trials - the gold standard for clinical drug evaluation -can't always predict adverse events in real-world settings. For the new cancer therapies, observational cohort studies (OCSs) can help evaluate their effects in broader populations and provide valuable information for future clinical trials.

Entities:  

Year:  2010        PMID： 22478817      PMCID： PMC2899798     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  26 in total

1.  A comparison of observational studies and randomized, controlled trials.

Authors:  K Benson; A J Hartz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Dangerous deception--hiding the evidence of adverse drug effects.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2006-11-23       Impact factor: 91.245

3.  The risk associated with aprotinin in cardiac surgery.

Authors:  Dennis T Mangano; Iulia C Tudor; Cynthia Dietzel
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

Review 4.  Primer: challenges in randomized and observational studies.

Authors:  Robert Landewé; Désirée van der Heijde
Journal:  Nat Clin Pract Rheumatol       Date:  2007-11

Review 5.  From randomized controlled trials to observational studies.

Authors:  Stuart L Silverman
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

6.  Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.

Authors:  Lodovico Balducci; Hafez Al-Halawani; Veena Charu; Jennifer Tam; Seta Shahin; Lyndah Dreiling; William B Ershler
Journal:  Oncologist       Date:  2007-12

7.  Limits of observational data in determining outcomes from cancer therapy.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006.

Authors:  C Michael Gibson; Yuri B Pride; Paul D Frederick; Charles V Pollack; John G Canto; Alan J Tiefenbrunn; W Douglas Weaver; Costas T Lambrew; William J French; Eric D Peterson; William J Rogers
Journal:  Am Heart J       Date:  2008-11-01       Impact factor: 4.749

10.  Barriers to clinical trial participation by older women with breast cancer.

Authors:  M Margaret Kemeny; Bercedis L Peterson; Alice B Kornblith; Hyman B Muss; Judith Wheeler; Ellis Levine; Nancy Bartlett; Gini Fleming; Harvey J Cohen
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
View more
  5 in total

1.  Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study.

Authors:  Sebastian Ochenduszko; Mirosława Puskulluoglu; Kamil Konopka; Kamil Fijorek; Agnieszka Julia Slowik; Michał Pędziwiatr; Andrzej Budzyński
Journal:  Ther Adv Med Oncol       Date:  2017-02-07       Impact factor: 8.168

2.  Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.

Authors:  Thomas Delate; Erin J Aiello Bowles; Roy Pardee; Robert D Wellman; Laurel A Habel; Marianne Ulcickas Yood; Larissa Nekhlyudov; Katrina A Goddard; Robert L Davis; Catherine A McCarty; Adedayo A Onitilo; Heather Spencer Feigelson; Jared Freml; Edward Wagner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-15       Impact factor: 4.254

3.  Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study).

Authors:  Nicholas Obermüller; Alexander R Rosenkranz; Hans-Walter Müller; Dennis Hidde; András Veres; Sabine Decker-Burgard; Isolde Weisz; Helmut Geiger
Journal:  Int J Mol Sci       Date:  2017-09-28       Impact factor: 5.923

4.  The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.

Authors:  Neil Gittoes; Lars Rejnmark; Steven W Ing; Maria Luisa Brandi; Sigridur Björnsdottir; Stefanie Hahner; Lorenz C Hofbauer; Pascal Houillier; Aliya A Khan; Michael A Levine; Michael Mannstadt; Dolores M Shoback; Tamara J Vokes; Pinggao Zhang; Claudio Marelli; John Germak; Bart L Clarke
Journal:  BMC Endocr Disord       Date:  2021-11-20       Impact factor: 2.763

5.  Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer.

Authors:  John R Bergquist; Cornelius A Thiels; Christopher R Shubert; Tommy Ivanics; Elizabeth B Habermann; Santhi S Vege; Travis E Grotz; Sean P Cleary; Rory L Smoot; Michael L Kendrick; David M Nagorney; Mark J Truty
Journal:  Cancer Med       Date:  2021-07-21       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.